The pharmaceutical company Novo Nordisk disputes the additional charge of 1 billion rubles to it. taxes

The Russian structure of the Danish pharmaceutical company Novo Nordisk, LLC Novo Nordisk, filed a lawsuit against the Federal Tax Service Inspectorate No. 31 for Moscow with the Moscow Arbitration Court. As follows from the file of the case, she asks to invalidate the decision of the tax authorities “on holding liable for committing a tax offense in terms of additional VAT charges on expenses worth more than 1 billion rubles.” Other details are not given there. A hearing in this case has been scheduled for August 21. The Russian office of Novo Nordisk declined to comment. In the Federal Tax Service, Vedomosti’s request was left unanswered.

Novo Nordisk was founded in 1923 in Denmark. Today, the company is one of the largest global manufacturers of insulin (in 2021, its share in the global market for such drugs was estimated at about 30%). The Russian representative office of Novo Nordisk was opened in 1991, in 2015 the pharmaceutical company launched a plant for the production of insulin with an area of ​​13,000 square meters in the Kaluga region. m. In March last year, the manufacturer announced the termination of investment in marketing and new clinical trials in Russia. Despite this, the revenue of Novo Nordisk LLC in 2022 according to RAS increased by almost 17% to 15 billion rubles, net profit amounted to more than 689 million rubles.